RBC Capital Markets has raised its price target on Siemens Healthineers to €48 from €45, following the debut of Varian's new Accela radiotherapy system at the annual meeting of the American Society for Radiation Oncology (ASTRO). The move signals growing confidence in the German medical technology giant's cancer-care division, which has been a key growth driver since Siemens acquired Varian in 2021.
What is Accela and why does it matter?
Accela is a next-generation radiotherapy system developed by Varian, the cancer-treatment arm of Siemens Healthineers. Radiotherapy uses targeted radiation to destroy cancer cells, and Accela is designed to treat more patients per day than existing systems. RBC analysts believe the launch at ASTRO supports Varian's claims that Accela can increase patient throughput and potentially expand the pool of patients who qualify for radiotherapy—a critical factor for hospitals weighing capital investments.
For hospital systems, buying a major piece of equipment like a radiotherapy machine is a significant capital expenditure. Purchases typically hinge on regulatory approvals and robust clinical evidence, not just marketing hype. RBC notes that the ASTRO presentation provided enough detail to reinforce the system's potential, which is why the bank sees more upside in the stock.
Regulatory timeline and what to watch
The path to market for Accela is still in progress. RBC expects CE mark approval—the regulatory certification required to sell medical devices in the European Union—in November 2026. In the United States, clearance from the Food and Drug Administration (FDA) is flagged for early 2027. These timelines are crucial because they determine when Varian can start booking orders and when revenue from Accela will begin to flow.
Investors will be watching for any updates on these regulatory milestones, as delays could push back the financial benefits. Conversely, earlier-than-expected approvals could provide a further boost to the stock.
What it means for investors
For everyday investors, the price target increase is a signal that RBC sees the risk-reward balance tilting favorably for Siemens Healthineers. The stock has been under pressure in recent years due to supply chain issues and slower-than-expected recovery in China, but the company's imaging and cancer-care businesses remain strong. The Accela launch could be a catalyst that helps the company regain momentum.
However, it's important to remember that a price target is just one analyst's view. The actual stock performance will depend on execution, regulatory outcomes, and broader market conditions. Investors should consider their own risk tolerance and portfolio diversification before making any decisions.
In the broader context, medical technology companies like Siemens Healthineers are often seen as defensive plays because healthcare demand is relatively stable regardless of economic cycles. But they are not immune to challenges such as currency fluctuations, competition, and regulatory hurdles.
Broader market context
The move comes amid a mixed environment for European healthcare stocks. While some companies have benefited from innovation and strong demand, others have faced headwinds from pricing pressures and geopolitical tensions. Siemens Healthineers' focus on high-growth areas like cancer care and precision medicine positions it well for long-term trends, but near-term volatility is always possible.
Investors may also draw parallels to other recent analyst actions in the sector. For instance, Publicis beat Q3 forecasts and kept its 2026 growth target, showing that companies with clear strategic focus can outperform. Similarly, Schneider Electric raised its 2026 profit target on strong AI data center demand, highlighting how specific catalysts can drive analyst upgrades.
RBC's move on Siemens Healthineers is not an isolated event. The bank has been active in adjusting targets across sectors, as seen with its coverage initiation on DHL with an outperform rating and its target cut on General Dynamics due to weaker Gulfstream outlook. These actions reflect a nuanced view of different industries and companies.
Bottom line
RBC's increased price target on Siemens Healthineers is a vote of confidence in the company's ability to innovate and grow its cancer-care business. The Accela system, if approved on schedule, could be a meaningful revenue contributor. But investors should keep an eye on regulatory timelines and the company's overall execution. As always, it's wise to do your own research and consider how this fits into your broader investment strategy.
